STUDresearch · Non-peptide

Methylene Blue

Also known as

MB · methylthioninium chloride · methylthioninium · USP methylene blue · pharmaceutical-grade methylene blue · ProvayBlue (clinical IV brand context) · Proveblue (clinical brand context) · methylene blue USP · MB drops / oral solution (community form) · LMTM / LMTX / TRx0237 / hydromethylthionine (related tau-aggregation derivative — not the same consumer MB) · Rember (older methylthioninium chloride AD program context)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Non-peptide Some talk Systemic Oral / IV Mitochondrial & metabolic compounds

Systemic dye with oral and intravenous exposure; clinical methemoglobinemia use and community nootropic use are different evidence contexts.

What people say Methylene blue is a systemic phenothiazine dye. Its approved IV use for acquired methemoglobinemia, controlled oral research at hundreds of milligrams, and unverified community oral nootropic use are distinct evidence contexts. Doses people talk about

Observed lower fixed oral accounts1 and 3 mg oral

The 1 mg amount followed a break in a longer self-report; the separate 3 mg first-use account included several other supplements and no blue urine.

Observed 5–8 mg account5–8 mg/day oral

Same author described perceived benefits within days, then light sensitivity and chronic headaches before stopping.

Observed 15 mg account~15 mg/day oral

Author described immediate calm and clarity, blue urine and later reduced perceived stimulant effects; dexamphetamine and caffeine were concurrent.

Labeled acquired-methemoglobinemia use1 mg/kg IV

PROVAYBLUE is given over 5–30 minutes; the label allows one repeat after one hour if specified criteria persist.

Preserved ICU infusion context0.25–2 mg/kg/h IV

The preserved profile describes this as a possible monitored continuous infusion after an IV bolus in refractory vasoplegia literature; it is not the methemoglobinemia label or consumer use.

These are separate reports and use cases, not a progression. Fixed milligrams, weight-based IV doses and mg/kg/hour infusion rates must remain distinct; no amount was inferred from drop count alone.

Half-life & effect duration

Half-life in the body: IV · whole-blood studyAbout 5.25 hours
IV · ProvayBlue labelAbout 24 hours
Delayed-release MMX · 200 mg studyAbout 14–27 hours
Delayed-release MMX · 400 mg studyAbout 6–26 hours
Felt duration people report: Positive accountsSame-day changes or benefits across days
Other experiencesLater headaches, no consistent duration, or an acute adverse episode with caffeine and other compounds

Timing context & sources

How it may feel Reports ranged from same-day clarity to no clear benefit, headache/light sensitivity after days, vivid dreams and a hospital-evaluated exercise episode. That exercise account also disclosed two espressos and very-low-dose retatrutide, so attribution remains unresolved. Blue urine occurred in one account but not another and does not prove benefit.

Cycles people discuss Community use ranged from one exposure to daily use over months, with breaks or stopping after adverse effects. These habits are not validated cycles, and long-term healthy-user outcome data remain thin. Timing Community use is usually placed in the morning or early day because later doses can feel wired or disrupt sleep. Food timing varies with GI tolerance, and same-morning red/NIR is a habit rather than a required clock; reports do not establish a universal bedtime cutoff. Stacks Co-supplements, caffeine and prescribed stimulant exposure confound the inspected reports. No reviewed combination or “most common” stack is established. Access talk USP / pharma-grade vs aquarium / industrial is the whole access argument. Fish-tank dye is the 2025–26 first-timer trap. Labs people mention G6PD before the experiment is the lab 2026 safety threads actually name — not a nootropic scoreboard. Watch for Serotonin syndrome (critical): Potent reversible MAO-A inhibitor; serious or fatal serotonin toxicity reported with serotonergic drugs (SSRIs, SNRIs, MAOIs, and others). FDA warning territory; perioperative IV dye cases well documented. Symptoms can include agitation, hyperthermia, rigidity, tremor, tachycardia, sweating, seizures.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A seven-person 100 mg IV study estimated a 5.25-hour terminal whole-blood half-life.

Healthy volunteers received 100 mg IV and oral methylene blue, and IV whole-blood concentration declined multiphasically.

Tiny study with its own assay and formulation; it is not interchangeable with the current IV product label or oral community use.

Pharmacokinetics and organ distribution of intravenous and oral methylene blue (opens in a new tab)Seven healthy volunteers received 100 mg IV and oral methylene blue; IV whole-blood decline was multiphasic with an estimated terminal half-life of 5.25 hours and oral AUC was much lower.Tiny study using a specific assay and 100 mg formulations; the 5.25-hour IV estimate should not be merged with other products, matrices or oral microdoses. PubMed abstract content was reviewed.

Half-life in the body

The PROVAYBLUE IV label reports an approximate 24-hour human half-life.

The same label describes a 2 mg/kg five-minute IV infusion for PK characterization and a 1 mg/kg acquired-methemoglobinemia dose.

Product-label estimate for intravenous methylene blue; it does not establish oral drop kinetics or subjective effect duration.

DailyMed PROVAYBLUE methylene blue injection label (opens in a new tab)Approved acquired-methemoglobinemia dose is 1 mg/kg IV over 5–30 minutes with at most one repeat after one hour; label PK reports an approximate 24-hour human half-life and warns about serotonin syndrome and G6PD-related hemolysis.IV prescription product and indication; not an oral nootropic label or evidence for continuous ICU infusions.

Half-life in the body

Delayed-release oral MMX tablets produced 14–27-hour half-lives after 200 mg and 6–26 hours after 400 mg.

Healthy volunteers received a single tablet after two liters of bowel preparation; median peak was 16 hours.

Bowel-prep delayed-release formulation at high fixed doses, not consumer drops, ordinary capsules or an approved cognitive regimen.

Methylene blue MMX tablets for chromoendoscopy (opens in a new tab)Healthy volunteers received single 200 or 400 mg oral MMX tablets after bowel preparation; median peak was 16 hours, and half-life ranged 14–27 hours after 200 mg and 6–26 hours after 400 mg.Bowel-prep delayed-release MMX formulation at hundreds of milligrams; not ordinary oral drops or low-dose community products. PubMed abstract content was reviewed.

Felt duration people report

The inspected community evidence does not establish one felt-onset or duration window.

Reports included same-day perceived changes after 3 or 15 mg, benefits and later headaches across days at 5–8 mg, and an acute exercise-associated adverse episode after about 7–7.5 mg alongside two espressos and very-low-dose retatrutide.

Anonymous self-reports with unverified products, co-supplements, caffeine, prescribed stimulant exposure, very-low-dose retatrutide and exercise or stress confounding cannot establish causality, safety or prevalence.

Reddit r/Biohackers — Experience with Methylene blue (opens in a new tab)Same author reported 5–8 mg daily with perceived brain-fog and circulation changes within days, then light sensitivity and chronic headaches; after stopping and restarting near 1 mg daily for two months, they described steadier energy while noting other life changes.Anonymous self-report, approximate drop conversion, unverified product and multiple lifestyle changes; cannot establish efficacy or safe dosing.
Reddit r/Biohackers — First experience with Methylene Blue (opens in a new tab)Author reported 3 mg orally with several other supplements, perceived same-session exercise and mood changes, vivid dreams, and lower HRV plus higher sleeping heart rate the next morning.Single anonymous, highly stacked report with no control and self-measured physiology.
Reddit r/Biohackers — Methylene blue and stimulants (opens in a new tab)Author reported about 15 mg/day, immediate calm and mental clarity, blue urine, then reduced perceived effects of coffee and prescribed dexamphetamine after several days.Anonymous self-report with prescribed stimulant and caffeine co-exposure, unverified product and no medical confirmation of interaction.
Reddit r/Biohackers — first use before workout (opens in a new tab)Same author described about 7–7.5 mg before exercise, prolonged tachycardia, chest tightness, blurry vision and dyspnea; hospital blood work and heart/lung scans were reported as unrevealing, and the author stopped.Anonymous recent report with inconsistent drop-total wording, estimated heart rate, workout stress, two espressos, very-low-dose retatrutide, creatine and a multivitamin, and no posted medical records; it cannot establish causality.

What people say 17

Focus / mental clarity (users): Low oral fixed doses — sharper attention, less brain fog, or a clean “edge” on high-demand days; highly variable and confounded by sleep, caffeine, and stacks. forum
Energy / fatigue narratives: Steadier daytime mental energy or less mid-day crash claimed in multi-week oral microdose logs; no large healthy-user energy RCT standard. anecdote
Anti-aging / skin tonic hype: Longevity and topical skin claims are common in content marketing; long-term human outcome trials for aging endpoints do not match the hype volume. forum
Sparse honesty: Most nootropic claims rest on small acute human imaging, animal hormesis, and self-tracking — not multi-year cognitive-outcome RCTs in healthy adults. forum
Memory retrieval (human imaging): Rodriguez et al., Radiology 2016 (PMID 27351678) — double-blind RCT, n=26 healthy adults; single oral USP dose 280 mg (~4 mg/kg for 70 kg); fMRI ~1 h post-dose showed increased activity in attention/short-term memory networks and enhanced memory retrieval (~7% often cited in press summaries). trial
Sustained attention fMRI: Same Rodriguez design reported increased functional MR response during psychomotor vigilance / sustained-attention tasks after that single oral dose. trial
Animal memory enhancement: Rodent work (Gonzalez-Lima lab and related) repeatedly finds memory retention benefits in a low band often centered near ~0.5–4 mg/kg, with ~4 mg/kg frequently called a reliable single-dose enhancer in object recognition / habituation paradigms; high doses reverse. animal
Mood / residual bipolar depression: Historical psych literature — Naylor et al. 2-year double-blind crossover (lithium-maintained bipolar): 300 mg/day oral MB year vs 15 mg/day year; less severe depression on 300 mg (17 completers; small trial, blindness/placebo limitations noted by authors). trial
Alda-class bipolar residual symptoms: Later randomized crossover work used ~195 mg/day vs 15 mg active-comparator low dose (urine color blinding); mood-score improvements (including MADRS-class measures) discussed on the higher arm in lamotrigine-stabilized residual-symptom patients. trial
Methemoglobinemia (established): IV 1–2 mg/kg under medical care reduces metHb and restores oxygen-carrying hemoglobin function — the main approved clinical use. trial
ICU / vasoplegia (hospital literature): IV methylene blue used off-label for refractory vasoplegic shock (e.g., post-CPB) via NO–sGC pathway effects; initial ~1–2 mg/kg with possible infusion — not consumer DIY. trial
Neuroprotection (preclinical): Oxidative-stress, ischemia, and neurodegenerative model papers support low-dose mito/redox protection narratives. animal
Near-IR / red-light synergy (research): Gonzalez-Lima & Auchter-type work pairs low-dose MB with near-infrared photobiomodulation for neurometabolic protection — basis for popular “red + blue” stack lore. trial
vs NAD stacks framing: Positioned as a cheap, old-drug electron-shuttling adjunct next to NMN/NR/NAD+ and CoQ10/PQQ — mechanistic complementarity talk without head-to-head outcome RCTs. forum
vs SS-31 / MOTS-c framing: MB = small-molecule redox cycler / dye; SS-31 = cardiolipin-targeting peptide; MOTS-c = mito-derived peptide signaling — adjacent mito aisle, different tools. forum
LMTM / tau programs (related, not identical): Hydromethylthionine mesylate (LMTM/LMTX/TRx0237) and older Rember methylthioninium programs target tau aggregation in AD/FTD pipelines — frequently confused with consumer oral MB drops; different formulation, dose culture, and regulatory status. trial
PTSD extinction adjunct interest: Historical clinical-trial interest (e.g., post-exposure oral MB in extinction-learning designs, including ~260 mg/day class PTSD HELP-trial context in secondary tables) — research path, not a consumer protocol. trial

Doses people talk about 22

Ultra-low / microdose fixed band (community): Roughly ~0.5–4 mg total oral daily appears in cautious “start low” charts and some longevity-protocol blogs that treat sub-5 mg as the practical cognitive window. forum
Common nootropic fixed band (community): Roughly ~5–15 mg oral total per day is the range most often repeated in nootropic/peptide-catalog style guides as self-reported practice, not trial-validated protocols. forum
Weight-based community cognitive talk: Some protocols restate ~0.5–1 mg/kg once daily oral for “brain health/energy,” which for a 70–80 kg adult lands near ~35–80 mg — higher than the 5–15 mg fixed-dose camp and debated as already mid-curve. forum
Capsule / tablet forms: Fixed 5 / 10 / 25 / 50 mg-class solids appear in compounded and gray-market catalogs — purity and true content still a quality problem; capsules skip dilution math but not source risk. forum
Timing: Morning or early day preferred in community logs; late dosing associated with sleep disruption or wired feeling in a subset. forum
Food: Light meal or with water dilution common; empty-stomach for “faster edge” lore vs with food if GI-sensitive — no single standard. forum
Start-low culture: Nearly universal community advice given hormesis and MAO-A risk — begin at the bottom of the fixed-mg band rather than jumping to research mg/kg figures. forum
Dropper-count camp: 2026 X posts argue 9 drops vs 12 the next week — without a stated mg/drop that math is theater. forum
mg/kg oral camp is the mix-up magnet: 0.5–1 mg/kg (tens of mg for a 70 kg adult) is still sold as “the cognitive sweet spot” in 2026 guides — that is the Rodriguez-class band, not the 5–15 mg dropper habit. forum
Three-tier confusion (core): Community writeups constantly mix (1) FDA IV metHb 1–2 mg/kg, (2) low oral cognition research including Rodriguez’s single 280 mg oral (~4 mg/kg), and (3) much smaller fixed oral microdoses (~0.5–20 mg) — conflating tiers is the most common dosing error. forum
Uncertainty flag: Non-USP dyes, unknown concentration, variable salt/hydrate labeling, and stack confounds make mg claims hard to compare across logs. forum
Flat 5 → 10 mg titration blogs: Some 2026 planners ignore bodyweight and step 5 mg (hold a week) → 10 mg (hold two weeks), with ~20 mg as a routine ceiling they do not want crossed. Different planet from 0.5–1 mg/kg oral blogs. forum
Historical bipolar oral bands: 15 mg/day (low/active-comparator arm) vs ~195–300 mg/day oral in residual depression / prophylactic crossover designs on background mood stabilizers — orders of magnitude above microdose culture and still research-era psych use, not a wellness default. trial
PTSD / extinction research oral: Secondary trial tables list oral daily totals in the mid-hundreds of mg class (e.g., ~260 mg/day in one completed PTSD extinction-learning listing) — supervised research, not forum microdosing. trial
Framing: Figures in this preserved profile dose table are discussed trial, label, clinic-chart, or community amounts for research/educational context only — not prescriptions, not advice, not instructions for human use. forum
Clinic-style titration charts (community/clinic PDFs): Examples published online step week 1 ~5 mg → week 2 ~10 mg → week 3+ ~15–20 mg daily AM, with a stated ceiling near ~0.5–1 mg/kg for “cognitive/mitochondrial” framing and warnings that higher can reverse into pro-oxidant effects — protocol marketing, not a labeled indication. forum
Broader research low band (mg/kg): Literature and reviews repeatedly cite low-dose ranges on the order of ~0.5–4 mg/kg oral (or comparable low IV research exposures) as the hormetic “beneficial” window in animal and human discussion; opposite effects often discussed above ~10 mg/kg class exposures. trial
Rodriguez single-dose cognition: 280 mg oral USP methylene blue once (~4 mg/kg assuming 70 kg) — acute imaging/memory design, not a daily microdose template. trial
Clinical methemoglobinemia IV (approved): Typically ~1 mg/kg IV (some labels/practice 1–2 mg/kg) infused over minutes under supervision; may repeat; maximum total-dose ceilings (e.g., ~7 mg/kg class warnings in product information) exist because higher IV exposure increases toxicity. trial
Vasoplegia / ICU (hospital): Often ~1–2 mg/kg IV bolus with possible continuous infusion ~0.25–2 mg/kg/h in refractory settings — monitored inpatient use only. trial
Hormetic / inverted-U rule of thumb: Community and reviews summarize roughly beneficial ~0.5–4 mg/kg, inflection ~4–10 mg/kg, and pro-oxidant / adverse territory often >~10 mg/kg (animal-heavy; human high-dose IV toxicity also documented). trial
High-dose IV toxicity note: Product monographs describe large IV doses (e.g., ~7 mg/kg class and overdoses far higher) causing nausea, chest pain, sweating, tremor, confusion, paradoxical methemoglobinemia, hemolysis risk, etc. trial

How it may feel 11

Same-day community reports varied: A stacked 3 mg account described perceived exercise and mood changes that day plus vivid dreams and next-morning HRV change; urine color did not change. forum
Acute contrast: One 15 mg/day author described immediate calm and clarity; another reported severe cardiopulmonary symptoms during exercise after about 7–7.5 mg alongside two espressos and very-low-dose retatrutide, then sought hospital care. forum
Days to months in one account: One author reported perceived benefit within days at 5–8 mg daily, then headaches and light sensitivity; after a break, roughly 1 mg daily for two months was described as steadier. forum
Weeks 1–2: Common personal checkpoint — keep daily microdose, switch to as-needed cognitive days, or stop after novelty wears off. forum
Weeks 3–4: Some claim steadier mental energy or less fog; others note diminishing returns / tolerance lore and take weekends off. forum
Months 2–3+: Public long-horizon structured tracking is thinner than short TikTok/Reddit experiments; continuous use often becomes habit/stack culture rather than measured endpoints. forum
No early effect: Community troubleshooting usually checks USP vs aquarium source, dropper concentration math, dose-too-high inverted-U lore (not automatic escalation), sleep/caffeine confounds, and serotonergic meds (stop-and-medical-review, not stack-through). forum
Benefits and harms both appeared at fixed milligrams: Inspected reports included perceived clarity at 15 mg/day, headache and light sensitivity at 5–8 mg/day, and a hospital-evaluated exercise episode after about 7–7.5 mg with caffeine and very-low-dose retatrutide co-exposure. forum
RFK-clip era: 2025 social volume jumped after a plane/blue-liquid clip — more first-timers mixing aquarium bottles, dropper math, and SSRI lists. forum
Urine color is inconsistent in reports: One 15 mg/day user saw blue urine, while a 3 mg user did not; discoloration reflects dye exposure or excretion, not cognitive benefit. forum
Weeks 6–12: Aligns with multi-week fMRI / aging-cognition research blocks discussed in literature (e.g., 2-week and 12-week USP MB administration designs in aging/MCI-interest protocols such as NCT02380573-class programs) — not proof of personal response. trial

Around the dose 7

Inspected timing context: Community reports described same-day effects, later adverse changes, or no clear benefit across different products and co-exposures. They do not establish a universal six-hour bedtime cutoff. forum
Food: With food or well-diluted water. Empty-stomach GI is a common quit. forum
Light: Same-morning red/NIR is the “red + blue” habit, not a required PK rule. forum
Marker: Blue-green urine means the dye moved — not that mitochondria improved. No tint is how people start arguing underdose vs fake bottle. forum
Hard stop: SSRI/SNRI/MAOI in the med list → 2025–26 Reddit treats that as off the table, not “start low.” forum
Drops vs capsules: Dropper math and stained teeth/tongue push people toward USP capsules or troches. Straw + rinse for liquids. forum
Cycle lore: 5-on/2-off shows up; there is no trial that made that the rule. forum

Cycles people discuss 9

Daily microdose habit: Continuous low oral fixed dose for weeks while tracking subjective cognition, sleep, and sides — dominant lifestyle pattern. forum
As-needed / high-demand days: Some use only on deep-work, travel, or exam-like days rather than every day. forum
Short personal trial: 2–4 weeks is a common “keep or drop” window before committing longer. forum
Time-off patterns: Weekend breaks, every-other-day, or 1 week off per month appear in logs to reassess baseline and manage tolerance lore. forum
Long open-ended use: Multi-month continuous oral use is discussed in longevity circles; robust long-term safety databases for unsupervised healthy-user microdosing remain limited compared with hospital metHb use. forum
No classic peptide 5-on/2-off standard: Cycling is ad hoc (budget, stain annoyance, sleep, diminishing returns), not a receptor-desensitization orthodoxy. forum
Stop rules (community): New serotonergic prescription, pregnancy questions, unexplained hemolysis symptoms, or G6PD diagnosis → stop and medical review, not “push through.” forum
Multi-week research-style blocks: 2-week and 12-week continuous oral USP administration appears in aging/cognition trial designs — not the same as influencer “forever blue” habits. trial
High-dose psych research was chronic: Bipolar crossover years at 15 vs 300 mg/day show that chronic oral MB has been studied medically at high mg — still not a template for unmonitored stacks with SSRIs. trial

Timing 11

Why daily oral in lifestyle use: Same-day cognitive window + multi-hour clearance supports once-daily (or as-needed same-day) oral use rather than weekly depot logic. forum
Blue fluids as marker: Urine/stool/saliva tint tracks exposure/excretion, not proof of mitochondrial benefit. forum
Metabolite / leuco form talk: Redox cycling between oxidized MB and reduced leucomethylene blue is central to mechanism writing; community sometimes oversimplifies this as “always antioxidant.” forum
Practical schedule: Morning oral so peak aligns with work block and sleep risk stays lower; red-light sessions often timed same morning within ~30–60 min of oral dose in stack guides (lore, not a required PK rule). forum
Oral exposure is formulation-specific: In a seven-person 100 mg study, oral whole-blood AUC was far below IV; delayed-release MMX tablets after bowel preparation produced very different timing. trial
Oral peak depends on formulation: In bowel-prepped volunteers taking 200 or 400 mg delayed-release MMX tablets, median blood peak was 16 hours; this does not describe consumer drops. trial
IV estimates differ by product and study: A seven-person 100 mg IV whole-blood study estimated 5.25 hours; the PROVAYBLUE IV label reports approximately 24 hours. Do not collapse them. trial
Oral MMX half-life ranges: After bowel preparation, 200 mg delayed-release tablets produced 14–27 hours and 400 mg produced 6–26 hours; these are not low-dose drop kinetics. trial
Urine excretion window: Blue-green urine discoloration commonly discussed from ~4–24 hours after dosing as dye clears renally. trial
CNS penetration: Lipophilic; high affinity for nervous tissue historically noted; rat work shows rapid brain uptake — drives cognitive timing and co-med risk talk. trial
MAO-A timing implication: Potent reversible MAO-A inhibition at nanomolar concentrations in vitro means serotonergic interaction risk is not limited to “high recreational” doses — perioperative single IV dye doses have triggered toxicity with SSRIs. trial

Stacks 12

Mito stack (most common): MB + CoQ10 (~100–200 mg with fat in many charts) ± PQQ ± NMN/NR/NAD+ — attribution heavily confounded; no combined Phase 3 lifestyle proof. forum
Red / near-infrared light: Same-day photobiomodulation (often ~630–670 nm class panels discussed, 5–10+ min near face/head in consumer guides) paired with low-dose oral MB — rooted in overlapping cytochrome/mito research, popularized as “red + blue.” forum
HBOT adjacency: Clinic content sometimes layers hyperbaric oxygen + red light + MB as a mitochondrial “stacked therapy” — expensive, multi-modality, confounded. forum
Nootropic adjacency: Caffeine, L-theanine, racetams, lion’s mane, creatine (~5 g) appear beside MB in stack blogs; watch overstimulation and any serotonergic nootropics/herbs. forum
Peptide adjacency: Named next to SS-31, MOTS-c, and humanin-class mito peptides in longevity forums — different mechanisms, same aisle. forum
Vitamin C redox debate: High-dose ascorbate + MB redox interactions are discussed in specialty literature (context-dependent, sometimes conflicting); not a casual must-pair. forum
Stack-building lore: Influencer charts sometimes suggest adding one compound at a time over weeks (e.g., MB first, then light, then NMN) — common-sense attribution advice, not trial design. forum
SLU-PP-915 / MOTS-c mito screenshots (2026): MB gets dropped next to oral ERR agonists and NAD — more attribution noise, same SSRI rule. forum
5-HTP / St. John’s wort / tramadol: 2025–26 “is my med list ok” threads still miss these even when they remember SSRIs. forum
Avoid serotonergic drugs (hard stop): SSRIs, SNRIs, MAOIs, many TCAs, and other serotonergic agents — serotonin syndrome risk is the dominant interaction; FDA boxed-warning class caution on methylene blue with serotonergic drugs. trial
Also watched serotonergics: Community and peri-op literature flag tramadol, meperidine, fentanyl-class opioids, methadone, buspirone, mirtazapine, bupropion, St. John’s wort, and some migraine/ADHD serotonergic agents as interaction concerns depending on pharmacology. trial
Do not stack two MAO inhibitors: Combining MB with classic MAOIs is treated as high-risk nonsense in safety writeups. trial

Access talk 4

USP / pharma-grade vs aquarium / industrial is the whole access argument. Fish-tank dye is the 2025–26 first-timer trap. forum
Amazon droppers vs compounded capsules vs troches: Same molecule claim, wildly different fill and metal talk. 2026 subreddit assay rounds are why people stopped trusting the cheapest bottle. forum
Not a peptide RUO vial. Oral dye. Hospital IV metHb product is a different shelf and a different mg/kg planet. forum
Compounding / clinic SKUs: Fixed 5/10/25 mg capsules exist; they skip dropper math, not the SSRI/G6PD rules. forum

Labs people mention 3

G6PD before the experiment is the lab 2026 safety threads actually name — not a nootropic scoreboard. forumtrial
CBC / hemoglobin: Hemolysis watch in G6PD talk; one 2025 r/Biohackers post credited MB for bringing hemoglobin back into range — anecdote, not a protocol. anecdote
No NAD kit required: People stack MB with NMN; they do not use methylene-blue urine color as a NAD test. forum

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 17

Blue-green fluids (expected): Urine, stool, and sometimes saliva tint hours after dose; can startle people and confound urine dipsticks — usually framed as benign dye effect. forum
Skin / sclera / mouth staining: Temporary blue tint of mouth, teeth, or rarely skin/sclera discussion after higher exposure or spills. forum
GI: Nausea, abdominal discomfort, diarrhea more common as dose rises or on empty stomach. forum
CNS: Headache, dizziness, restlessness, anxiety, or overstimulation in a subset — especially if dose overshoots the personal hormetic window or is stacked with stimulants. forum
Source quality (heavy metals): Aquarium, textile, and industrial grades may contain arsenic, lead, mercury, cadmium, chromium, or co-formulants (e.g., other fish meds) — community consensus is never for human oral use. forum
Gray-market under/over-labeling: Capsule and dropper products vary; COA and USP/pharma sourcing are the recurring quality themes. forum
Not risk-free because “old”: Hospital grandfathered/metHb use and long history ≠ unsupervised daily cognitive self-experimentation is proven safe lifelong. forum
Amazon assay drama (2026): r/methylene_blue testing threads claimed most sampled bottles failed independent assay (one round: 22 of 61 passed, 39 failed) — USP on the label is not a COA. forum
Dropper overshoot: Counting drops without mg/drop is how people jump from “microdose” to a messy mid-curve. forum
G6PD is not a vibe check: Hemolysis risk is the other hard contraindication next to serotonergic drugs — 2026 Reddit still tells first-timers they may not know they have it. trialforum
Serotonin syndrome (critical): Potent reversible MAO-A inhibitor; serious or fatal serotonin toxicity reported with serotonergic drugs (SSRIs, SNRIs, MAOIs, and others). FDA warning territory; perioperative IV dye cases well documented. Symptoms can include agitation, hyperthermia, rigidity, tremor, tachycardia, sweating, seizures. trial
G6PD deficiency (contraindication): Risk of hemolytic anemia — standard clinical contraindication; case reports of worsened hemolysis when used inappropriately. trial
High-dose / overdose toxicity: Paradoxical methemoglobinemia, hemolysis, cardiopulmonary symptoms, confusion, chest pain — product monographs describe severe features at high IV mg/kg exposures. trial
Renal impairment caution: Clinical dosing adjustments and single-dose limits appear in IV monographs for reduced eGFR — hospital context, but relevant to systemic exposure talk. trial
Pregnancy / lactation: Clinical product labeling restricts use; not a casual wellness experiment population in responsible community guidance. trial
Pulse ox / monitoring interference: Deep blue dye can interfere with some clinical monitoring/color-based assessments in hospital settings. trial
Psychiatric medication context: Any mood benefit discussion is inseparable from interaction risk — residual bipolar research used supervised high oral mg with stabilizers, not silent SSRI stacking. trial

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Half-life in the body

Half-life in the body

Felt duration people report

What people say 17

Doses people talk about 22

How it may feel 11

Around the dose 7

Cycles people discuss 9

Timing 11

More on what it is 7

Stacks 12

Access talk 4

Labs people mention 3

Storage notes 2

Related 8

Watch for 17

Timing context & sources